A Study of LY3473329 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events

Inclusion Criteria

• •Participants must be at least 40 years old
• •Participants with Lp(a) ≥175 nmol/L at randomization, measured at the central laboratory.
• •High risk for cardiovascular events defined as documented coronary artery disease (CAD), stroke, or peripheral artery disease or atherosclerotic cardiovascular disease (ASCVD) risk equivalents (familial hypercholesterolemia or type 2 diabetes).
• •Participants on the following medications according to local practice must be on a stable regimen for at least 4 weeks prior to randomization and expected to remain on a stable regimen through the end of the post-treatment follow-up period.
• •* lipid-lowering drugs
• •* testosterone, estrogens, anti-estrogens, progestins, selective estrogen receptor modulators, or growth hormone
• •Have a body mass index within the range 18.5 to 40 kilogram/square meter (kg/m²), inclusive.
• •Males who agree to use highly effective or effective methods of contraception may participate in this trial.
• •Women of childbearing potential (WOCBP) who agree to use highly effective or effective methods of contraception and women not of childbearing potential (WNOCBP) may participate in this trial.